目的 探讨雷公藤多苷片联合猪抗人淋巴细胞球蛋白治疗重型再生障碍性贫血的临床疗效。方法 回顾性分析2014年1月-2016年8月于宝鸡市人民医院治疗的76例重型再生障碍性贫血患者，根据不同的治疗方法将患者分为对照组和治疗组，每组各38例。对照组第1~5天静脉滴注猪抗人淋巴细胞球蛋白30 mg/（kg·d）。治疗组在对照组治疗基础上口服雷公藤多苷片，20 mg/次，3次/d。两组患者均连续治疗1年。观察两组患者的临床疗效，比较两组的血常规指标、T淋巴细胞亚群指标、不良反应发生率、复发和生存情况。结果 治疗后，对照组和治疗组的总有效率分别为71.1%、89.5%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组白细胞（WBC）、血小板（PLT）、血红蛋白（Hb）、网织红细胞（Ret）、中性粒细胞（ANC）水平均显著升高，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组血常规指标水平显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组CD4⁺、CD4⁺/CD8⁺水平均显著升高，CD8⁺水平显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组T细胞亚群指标变化显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗期间，治疗组各不良反应发生的例数均显著低于对照组，两组不良反应发生率比较差异具有统计学意义（P<0.05）。治疗后，治疗组1年复发率显著低于对照组，1年生存率显著高于对照组，两组比较差异具有统计学意义（P<0.05）。结论 雷公藤多苷片联合猪抗人淋巴细胞球蛋白治疗重型再生障碍性贫血疗效显著，可改善患者的免疫功能，有效提高患者生存率，降低复发率，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Tripterygium Glycosides Tablets combined with Porcine Anti-Human Lymphocyte Immunoglobulin in treatment of severe aplastic anemia. Methods Retrospective analysis of 76 patients with severe aplastic anemia in Baoji People's Hospital from January 2014 to August 2016 were divided into control and treatment groups according to different treatment methods, and each group had 38 cases. Patients in the control group were iv administered with Porcine Anti-Human Lymphocyte Immunoglobulin at the first to fifth day, 30 mg/(kg·d). Patients in the treatment group were po administered with Tripterygium Glycosides Tablets on the basis of the control group, 20 mg/time, three times daily. Patients in two groups were treated continuously for 1 year. After treatment, the clinical efficacy was evaluated, and blood routine indexes, T lymphocyte subsets indexes, the incidence of adverse reactions, recurrence and survival in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 71.1% and 89.5%, respectively, and there were differences between two groups (P < 0.05). After treatment, levels of WBC, PLT, Hb, Ret, and ANC in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the levels of blood routine indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment,CD4⁺ and CD4⁺/CD8⁺ in two groups were significantly increased, but CD8⁺ in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the T lymphocyte subsets indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). During the treatment, the numbers of adverse reactions in the treatment group were significantly lower than those in the control group, and the incidence of adverse reactions were statistically significant between two groups (P < 0.05). After treatment, the 1-year recurrence rate in the treatment group was significantly lower than that in the control group, and the 1-year survival rate was significantly higher than that in the control group, and there were differences between two groups (P < 0.05). Conclusion Tripterygium Glycosides Tablets combined with Porcine Anti-Human Lymphocyte Immunoglobulin has a significant effect in treatment of severe aplastic anemia, can improve the immune function of patients, effectively improve the survival rate of patients, and reduce the recurrence rate, which has a certain clinical application value.